Skip to main content
Displaying 1 - 12 of 22
Display:
12
24
48
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Pagination
Current page
1
Page
2
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy